Evidence map›Paper›PMID 31941771›Full record

ArticleJournal of virology2020

HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4

Jérémie Prévost, Cassandra R Edgar, Jonathan Richard, Steven M Trothen, Rajesh Abraham Jacob, Mitchell J Mumby, Suzanne Pickering, Mathieu Dubé, Daniel E Kaufmann, Frank Kirchhoff and 3 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. TIM-3, a potential target for sepsis therapy.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Jérémie Prévost *Centre de Recherche du CHUM, Montreal, Quebec, Canada.
Cassandra R Edgar *Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Jonathan RichardCentre de Recherche du CHUM, Montreal, Quebec, Canada.
Steven M TrothenDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Rajesh Abraham JacobDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Mitchell J MumbyDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Suzanne PickeringDepartment of Infectious Disease, King's College London School of Life Sciences and Medicine, Guy's Hospital, London, United Kingdom.
Mathieu DubéCentre de Recherche du CHUM, Montreal, Quebec, Canada.
Daniel E KaufmannCentre de Recherche du CHUM, Montreal, Quebec, Canada.
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Stuart J D NeilDepartment of Infectious Disease, King's College London School of Life Sciences and Medicine, Guy's Hospital, London, United Kingdom.
Andrés FinziCentre de Recherche du CHUM, Montreal, Quebec, Canada andres.finzi@umontreal.ca jimmy.dikeakos@uwo.ca.
Jimmy D DikeakosDepartment of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada andres.finzi@umontreal.ca jimmy.dikeakos@uwo.ca.
Centre Hospitalier de l’Université de Montréal · CAWestern University · CAGuy's Hospital · GBUniversität Ulm · DE

Funding

Assessing ADCC and Fc-mediated Protection against HIVR01AI148379 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI EVANS, DAVID T, FINZI, ANDRES · 2019 to 2023
$3.8M
Medical Research Council G0801937NIAID NIH HHS R01 AI148379Wellcome Trust 207442/Z/17/ZWellcome Trust WT098049AIA
6 · The paper itself

Abstract

Along with other immune checkpoints,

Indexed as

Down-RegulationCD4-Positive T-LymphocytesCell MembraneGene Expression RegulationHEK293 CellsHeLa CellsHepatitis A Virus Cellular Receptor 2HIV-1Human Immunodeficiency Virus ProteinsHumansInterferon-betaRNA, Small Interferingtrans-Golgi NetworkViral Regulatory and Accessory ProteinsViroporin ProteinsHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2Human Immunodeficiency Virus ProteinsInterferon-betaRNA, Small InterferingViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1HIVmembrane traffickingTim-3viral releaseVpu

Identifiers

PMID31941771
PMCPMC7081912
OpenAlexW3000236443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.